Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 1 of 3
Archive
Small Cap Feast
24 November 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:One Health Group plc (AQSE: OHGR), joins the Apex segment of the AQSE Growth Market.
Royal Mail not alone in benefiting from the pandemic
In the UK, the home delivery boom during the pandemic has clearly benefited many online operators while the fight against the coronavirus has thrown the spotlight on several biotechs
Archive
Ethernity Networks wins second sizeable 5G system contract
A look at the major movers on the London market on Friday
Archive
Grafton Group boosted by £520mln sale of merchanting business
A look at the major movers on the London stock market on Thursday
Archive
Shefa Gems to become tech cash shell
A look at some of the major movers in London on Tuesday
Proactive news headlines: Sareum, World High Life, Pelatro, Block Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum hails government funding initiative for new COVID-19 treatments as a “welcome source of funding”
Sareum is currently carrying out preclinical research to assess the potential of its candidate, SDC-1801, in Covid
Sareum Holdings focused on clinical trial application
Dr Tim Mitchell, chief executive of Sareum, said he believes there is a "clear opportunity to generate significant value for our shareholders over the next 12 months"
Sareum receives worldwide rights to FLT3 programme
FLT3 is investigating kinase inhibitors, which are designed to reduce immune system overreaction to viral infections such as coronavirus (COVID-19)
Archive
Argo Blockchain the top riser after cash influx from options and warrants conversion
A look at some of the major movers in London on Thursday
Sareum Holdings formally receives US patent protection for its pre-clinical cancer programme
The drug developer’s chief scientific officer, Dr John Reader, said: "The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets."
Sareum highlights good progress despite challenging period due to coronavirus
Chairman Stephen Parker said the drug developer’s key focus remains on advancing the development of its two TYK2/JAK1 programmes, namely SDC-1801, targeting autoimmune diseases, and SDC-1802, targeting cancer
Archive
Proactive news headlines: Sareum, Location Sciences, Alien Metals, Remote Monitored System …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum up as 'Nature' article identifies TYK2 as key causative genetic mechanism for coronavirus
The observation, which was published online as an Accelerated Article Preview by 'Nature' on December 11, 2020, is consistent with the scientific rationale supporting the company's recent successful UK Research & Innovation (UKRI) grant app
Sareum confirms UK grant award to research potential coronavirus treatment
The £174,000 grant will be used to investigate whether the firm's SDC-1801 therapy candidate can help to block an over-active inflammatory response in severe cases
Sareum announces amendment to licensing agreement for SRA737
SRA737 is a Checkpoint kinase 1 inhibitor currently in clinical development targeting solid cancers
Sareum secures grant for coronavirus research
The grant will be used to fund an investigation into the therapeutic potential of the company's SDC-1801 treatment on coronavirus patients
Sareum says progress has been good across a range of programmes
Company expects to hear this month whether it will receive grant funding for preliminary studies of a coronavirus (COVID-19) anti-inflammatory.
Sareum Holdings says it is close to winning US patent protection for cancer immunotherapy programme
Subject to certain formalities, the company expects the patent will be granted within the next three months
Sareum continues discussions with potential licensees for promising pre-clinical immunotherapies
Investors were told that investigational new drug-enabling work would be completed for at least one of its TYK2/JAK1 candidates by the end of the calendar year
Archive
Proactive news headlines: Sareum Holdings, Thor Mining, Bahamas Petroleum, Berkeley Energia, Integumen …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum Holdings says encouraged by conclusions from lupus study
An approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression
Archive
Small Cap Feast - Sareum Holdings; Red Rock Resources; Instem; Amryt Pharma; Westminster Group; Bango and more...
Sareum Holdings* 0.6p £18.4m (AIM:SAR) Completion of a fundraising in conjunction with an offer via PrimaryBid. The PrimaryBid Offer successfully completed and closed at 9:00 p.m. on 02 June 2020, raising gross proceeds of £303,722.40 at 0.
Sareum Holdings plans to raise £718,500 via share placing
The group also confirmed it “continues to engage with interested parties regarding the further development and potential commercialisation” of TYK2/JAK1 drugs SDC-1801 and SDC-1802
Sareum Holdings says CEO, Dr Tim Mitchell to give on-line presentation at BIO Digital 2020
The presentation will highlight Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively
Archive
Small Cap Wrap - Sareum Holdings; Genedrive PLC; Frontier IP; Scancell Holdings; Independent Oil & Gas and more...
Orosur Mining 1.8p £2.9m (AIM:OMI) The South American-focused gold developer and explorer, announced the appointment of Brad George, 54, as Non-Executive Director of the Company with immediate effect. Mr. George is a geoscientist by profess
Sareum Holdings agrees licensing deal with Shanghai listed firm
The deal covers the FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for acute myeloid leukaemia and other blood-borne cancers
Sareum reiterates plans to focus on cancer and autoimmune drug programmes
Ahead of the company’s annual meeting, chairman Dr Stephen Parker, said that in SDC-1802, the company has discovered a “potent, orally-available, small molecule contributor to the immune-oncology field, which could prove advantageous over t
Sareum says early findings from study of new potential cancer immuno-therapy garner interest at leading industry conference
“There was a good level of interest directed at novel immunotherapy mechanisms ... and we look forward to further discussions with interested parties"
Archive
Breakfast News - Sareum Holdings, Pantheon Resources, IG Design Group and more...
Set menuAIM:Total number of AIM Companies (Incl Susp):875*Total number of AIM Companies trading:791**as at close of business 14 October 2019Standard List** of Main Market:Total number of Standard List Companies(Incl Susp)
Sareum Holdings poster details released
Sareum Holdings' chief executive, Dr Tim Mitchell, will outline the potential of the company’s latest drug to fight a number of cancers when he attends the American Association for Cancer Research on October 29
Sareum looks towards clinical studies for novel autoimmune and cancer therapies
Sareum is looking to secure commercial licences for the late pre-clinical or early clinical stages of their development
Archive
Breakfast News - MediaZest, Sareum Holdings, Symphony Environmental Tech and more...
Set menu AIM: Total number of AIM Companies (Incl Susp): 879* Total number of AIM Companies trading: 795* *as at close of business 23 September 2019
Sareum Holdings to showcase potential of new cancer drug at leading industry conference
The poster presentation is based on pre-clinical work on its TYK2/JAK1 inhibitor, SAR-20351
Sareum confident partner will find funding solution for promising cancer drug
SRA737 could be worth up to US$88mln in future milestone payments and royalties, the company confirmed
Archive
Proactive news snapshot: Union Jack Oil, Oncimmune, Ariana Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Angus Energy considers sale of Brockham licences after disappointing drilling programme
A look at the day's major movers, including Rose Petroleum, Craneware, CVS, Adept4, Merlin, Mirriad and Costain
Investments and investor services
FTSE 100 closes higher on day and week as world leaders meet
The mid-cap FTSE 250 added over 147 points to close at 19,462 on Friday
Sareum notes decision by Sierra Oncology to explore options for future development of SRA737
SRA737 is a checkpoint kinase 1 that Sierra licensed from Sareum back in 2016
Archive
Proactive news snapshot: 88 Energy, Tekcapital, AFC Energy, SDX Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Kibo Energy the day's top riser as its moves to secure total ownership of the Bordersley project
A look at the day's major movers, including 88 Energy, Two Shields, Inland Homes, Avingtrans, Creightons, RM2 and RPS Group
Sareum raises £680k as it looks to take its TYK2/JAK1 inhibitors into the clinic next year
Sareum raised the money by selling 170.37mln new shares at 0.4p each – a 25% discount to Tuesday’s closing price
Archive
FTSE 100 still stuck in neutral; G20 meeting can't come soon enough
Bitcoin is up more than 10% but the shine has come off gold a bit
Investments and investor services
Maistro shares to become just a blurred memory
A look at the day's major movers, including Great Western Mining, Majestic Wine, Ascent, Ferguson and Just Group
Archive
Proactive news snapshot: Tekcapital, Quadrise Fuels International, Sareum Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum surges as it signals progress on pre-clinical programmes
"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to a
Archive
Proactive news snapshot: Argo Blockchain, Sareum Holdings, WideCells Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
EQTEC gives ground as it draws on its loan facility
A look at the day's major movers, including Carclo, Sareum, Karelian, Kier, Fulcrum, Microsaic, Dignity and Scapa
Sareum Holdings hails early-stage efficacy data for cancer drug
The latest update was provided at a America's largest and most prestigious cancer conference
Investments and investor services
FTSE 100 closes higher despite continued trade worries
The UK's blue-chip benchmark added over 23 points to close at 7,184
Immuno-oncology: All you wanted to know but were too afraid to ask
Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers
Gaming Realms surges after striking deal with SG Digital
A look at the day's major movers, including RA International, Genus, LiDCO, Just Group, Yu Group and Thomas Cook
Archive
Proactive news snapshot: Gaming Realms, Sareum Holdings, Anglo Asian Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum Holdings created drug to be showcased at leading cancer event next month
Sareum's partner Sierra Oncology has provided the essence of what it will share with delegates at the upcoming American Society of Clinical Oncology in Chicago
Archive
Proactive news snapshot: Sirius Minerals, AFC Energy, Location Sciences …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Solid State sparks rally with bullish trading update
A look at some of the biggest risers and fallers in London on Tuesday
Investments and investor services
Air Partners appoints MD of its charter division
A look at the day's major movers, including Quadrise, Intu Properties, Mediazest, Upland Resources, MX Oil and Angling Direct
Archive
Proactive news snapshot: Active Energy, Tekcapital, Sareum Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum Holdings jumps as it says new data on cancer drug to be released at top conference
The update is being presented in the form of two abstracts at the American Society of Clinical Oncology in Chicago
Investments and investor services
FTSE 100 closes at near seven month high as no news is deemed good news
The UK blue-chip index finished up around 63 points at 7,523
Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse models
After 50 days, eight out of ten mice achieved a complete response, which means there was no detectable sign of cancer anymore
Archive
Proactive news snapshot: Tekcapital, Mirada, European Metals Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Superdry investors in danger of losing their shirt after Dunkerton prevails in power struggle
A look at the day's major movers, including Clear Leisure, Proteome, Intercede, MP Evans, Zenith Energy, Infrastructure India and Sabien Technology
Investments and investor services
GAN trumpets winning of an industry award ... the shares fall
A look at the day's major movers, including Gulf Marine Services, Boxhill, Chesterfield Resources, Proton Power, Abcam, Tandem, Red Emperor and FFI
Archive
Proactive news snapshot: Shield Therapeutics, Plexus Holdings, 88 Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum boss “very pleased” with progress of flagship Chk1 inhibitor
US firm Sierra Oncology has licensed the molecule and the results from two early-stage ovarian cancer studies are due in the current half
Investments and investor services
FTSE 100 finishes ahead on US-China optimism; Rightmove top gainer
The UK blue-chip benchmark finished around 27 points higher at 7,134
Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data
Researchers in Texas found that SRA737, when combined with immunotherapy and low dose gemcitabine, had a “dramatic enhancement” in anti-tumour activity
Archive
Proactive news snapshot: Shanta Gold, Amryt Pharma, Greencoat UK Wind …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Block Energy, H&T Group, ClearStar …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal
The small-cap broker’s analysts noted that Bristol-Myers Squibb has agreed to acquire Celgene for US$74bn, with the combined entity to have six expected near-term product launches
Archive
Proactive news snapshot: Sunrise Resources, Taptica International, Physiomics …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: ValiRx, Avation, Sativa Investments …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Urals Energy tumbles again as war of words with Sergey Kononov intensifies
A look at the day's major movers, including redT, Rockfire, Oilex, SPDI and Orosur Mining
Sareum Holdings chairman says drug discovery group is making progress
At the company’s annual meeting, being held in the City of London, chairman Dr Stephen Parker will point to the progress of SRA737, which has been licensed to Sierra Oncology
Archive
Indivior investor call to be among the key highlights for Tuesday
Addiction drug firm Indivior is updating investors in the wake of a recent decision by the US Court of Appeals.
Archive
Fed could be Grinch-like in final full trading week before Christmas, but BoE seen more festive
Aside from the UK and US rate decisions, the latest UK inflation and retail data will be closely eyed as well in the absence of almost anything on the corporate diary
Archive
Proactive news snapshot: Redx Pharma, Active Energy , Live Company …
A glance at some of the day's highlights from the Proactive Investors newswire
Webis weak on limited California license renewal; Kier Group drops on cash call
A look at some winners and losers in the UK equity market on Friday
Sareum’s SRA737 Chk1 inhibitor impresses once again
Sierra Oncology, the US firm which is licensing Sareum’s SRA737 compound, published more data overnight
FTSE 100 closes lower as G20 summit begins and trade worries continue; housebuilders fall
The premier index of UK shares finished down nearly 59 points at 6,980. Mid-cap cousin FTSE 250 shed over 128 points at 18,480.
Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer
Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer
Archive
Proactive news snapshot: VR Education, Bigdish, Learning Technologies …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Haydale Graphene Industries, Tissue Regenix, to Hurricane Energy …
A glance at some of the day's highlights from the Proactive Investors newswire